Halozyme Therapeutics (HALO) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is HALO's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Halozyme surges 43.1% in six months on strong ENHANZE-driven royalties and higher revenue guidance.…

Halozyme's royalty revenues surged 45.8% in the first nine months of 2026, prompting higher guidance.…

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.…

Here is how Halozyme Therapeutics (HALO) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.…

HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours.…

Halozyme lifts its 2026 outlook after a 44% royalty surge, as ENHANZE expansion, Hypercon trials and a Merck patent dispute draw investors' focus.…

SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of th…

Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & …

Halozyme Therapeutics NASDAQ: HALO raised its full-year 2026 guidance after reporting record third-quarter revenue and royalties, driven by growth in established partner products and contributions from newer subcutaneous…

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates …

Halozyme Therapeutics (HALO) came out with quarterly earnings of $2.39 per share, beating the Zacks Consensus Estimate of $2.29 per share. This compares to earnings of $1.72 per share a year ago.…

Total Revenue Increased 39% YOY to $493 million Royalty Revenue Increased 44% YOY to $341 million Raising 2026 Financial Guidance Ranges: Total Revenue of $1.860 - $1.925 billion, YOY Growth of 33% - 38% Royalty Revenue …

Evaluate the expected performance of Halozyme Therapeutics (HALO) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for …

Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.…

Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

FORT WORTH, Texas--(BUSINESS WIRE)--AMTC-- Bell Textron Inc., a Textron Inc. (NYSE: TXT) company, announced during the annual Air Medical Transport Conference (AMTC) 2026 the purchase order for a Bell 407GXi to HALO-Flig…

Gibbs Wealth Management increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 140.0% in a recent quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned …

SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its third quarter 2026 financial and operating results on Thursday, November 5, 2026, follo…

Halozyme Therapeutics, Inc. (HALO) shares are up 910% since March 2014.…

First Citizens Bank and Trust Co. decreased its position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 59.5% during a recent quarter, according to its most recent filing with the Securities and Exchange Commission (SE…

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one o…

Expanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targets SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announce…

SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors.…

SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes…

SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion …
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

